On November 28, Professor Chen Chun, Vice President of the Seventh Affiliated Hospital of Sun Yat-sen University, leader of the Department of Pediatric Hematology and Oncology, Director of the Department of Pediatrics of Sun Yat-Sen University School of Medicine, Professor Huang Junbin, director of pediatrics, visited Shenzhen Cell Valley for exchange and visit. Our chairman Professor Shi Yuanyuan, deputy General manager Tang Xiaomeng, commercial director Tang Hui, Research and development Department Minister Zhao Lijun, Marketing Department Minister Sun Rui and other warm reception.

Accompanied by Sun Rui, Director of the Marketing Department, the team visited the smart exhibition hall, digital monitoring platform, production and quality control workshop. Made a preliminary understanding of the company's strategic development layout, enterprise development history, core team, core technology patents, history and current situation of cell therapy, the role and advantages of retroviral vector in cell therapy, Shenzhen and Zhongshan production, research and development, quality management and industrialization talent training bases. And have a deeper understanding of the comprehensive and one-stop service process from basic scientific research to clinical application transformation provided by Shenzhen Cell Valley.

At the symposium, Professor Shi Yuanyuan warmly welcomed the arrival of clinical experts from the Seventh Affiliated Hospital of Sun Yat-Sen University. Afterwards, the two sides exchanged views on the project landing plan such as cooperating to build a cell therapy platform, conducting IIT clinical research exploration in the direction of children's blood tumors, and transforming the direction of follow-up innovation.

Minister Sun Rui introduced in detail the core advantages of Shenzhen Cell Valley and the use of domestic leading retroviral vector GMP grade industrial production process. Professor Shi Yuanyuan said that cell therapy has made remarkable achievements in improving patient survival and reducing the burden of cancer. We use our own industrial production process and other advantages to provide high-quality and safe cell preparation services with a number of first-class hospitals, and cooperate to jointly promote the clinical research and application development of cell therapy. Dozens of patients with recurrent or drug-resistant blood tumors who did not respond to previous treatment experienced significant remission after treatment with CAR T cells prepared by the Cell Valley team. At the same time, Cell Valley's recently launched NK and CAR-NK cell therapy products are widely used in clinical studies of hematologic tumors. Shenzhen Cell Valley has always adhered to the mission values of "cells benefit all beings and genes create the future", and is committed to solving the key constraints such as technology, cost, production capacity and talent in cell therapy drugs/clinical treatment, and opening up more treatment ways for patients.

Chen Chun said that cell therapy is becoming a new focus of the development of the medical and health industry, the future cell clinical treatment model will be full cycle and all-round, its popularization and promotion cannot be achieved without the unremitting technological development of the scientific research team and the application and transformation of the high-level clinical treatment team.

Both parties said that they will give full play to their respective technical resources, core teams and platform advantages to jointly promote the scientific research and clinical application of cell therapy in children's blood tumors.